DBV Technologies (DBVT) Cash & Equivalents (2014 - 2026)
DBV Technologies (DBVT) reported Cash & Equivalents of $229.2 million for Q1 2026, up 1668.25% year-over-year from $13.0 million in Q1 2025, and up 18.02% on a QoQ basis from $194.2 million in Q4 2025.
DBV Technologies (DBVT) has 13 years of Cash & Equivalents data on file, last reported at $229.2 million in Q1 2026.
- Quarterly Cash & Equivalents rose 1668.25% year-over-year to $229.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $229.2 million (up 1668.25% YoY) and the FY2025 annual result came in at $194.2 million, up 498.35% from the prior year.
- Cash & Equivalents advanced to $229.2 million in Q1 2026 per DBVT's latest filing, from $194.2 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $248.0 million in Q2 2022 and bottomed at $13.0 million in Q1 2025.
- The 5-year median for Cash & Equivalents is $141.4 million (2023), against an average of $132.7 million.
- The widest annual swing landed in 2025, when Cash & Equivalents tumbled 87.23%; it then jumped 1668.25% in 2026.
- Tracing DBVT's Cash & Equivalents over 5 years: stood at $209.2 million in 2022, then sank by 32.42% to $141.4 million in 2023, then slumped by 77.04% to $32.5 million in 2024, then surged by 498.35% to $194.2 million in 2025, then gained by 18.02% to $229.2 million in 2026.
- Per Business Quant, the three latest DBVT Cash & Equivalents figures stand at $229.2 million (Q1 2026), $194.2 million (Q4 2025), and $69.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 1.91 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.49 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.96 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.71 Bn |
| 10 | DBV Technologies | 8.00 Bn | 7.77 Bn | -3.90 Mn | 229.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 229.20 Mn |
| Dec 31, 2025 | 194.20 Mn |
| Sep 30, 2025 | 69.84 Mn |
| Jun 30, 2025 | 103.20 Mn |
| Mar 31, 2025 | 12.96 Mn |
| Dec 31, 2024 | 32.46 Mn |
| Sep 30, 2024 | 46.40 Mn |
| Jun 30, 2024 | 66.21 Mn |
| Mar 31, 2024 | 101.53 Mn |
| Dec 31, 2023 | 141.37 Mn |
| Sep 30, 2023 | 149.14 Mn |
| Jun 30, 2023 | 173.96 Mn |
| Mar 31, 2023 | 192.29 Mn |
| Dec 31, 2022 | 209.19 Mn |
| Sep 30, 2022 | 212.67 Mn |
| Jun 30, 2022 | 247.97 Mn |
| Mar 31, 2022 | 74.10 Mn |
| Dec 31, 2021 | 77.30 Mn |
| Sep 30, 2021 | 98.20 Mn |
| Jun 30, 2021 | 125.50 Mn |
| Mar 31, 2021 | 152.46 Mn |
| Dec 31, 2020 | 196.35 Mn |
| Sep 30, 2020 | 221.40 Mn |
| Jun 30, 2020 | 252.92 Mn |
| Mar 31, 2020 | 287.44 Mn |
| Dec 31, 2019 | 190.41 Mn |
| Sep 30, 2019 | 136.61 Mn |
| Jun 30, 2019 | 120.53 Mn |
| Dec 31, 2018 | 140.13 Mn |
| Sep 30, 2018 | 160.37 Mn |
| Jun 30, 2018 | 164.55 Mn |
| Dec 31, 2017 | 162.34 Mn |
| Jun 30, 2017 | 218.46 Mn |
| Dec 31, 2016 | 276.92 Mn |
| Jun 30, 2016 | 326.26 Mn |
| Dec 31, 2015 | 354.46 Mn |
| Jun 30, 2015 | 115.53 Mn |
| Dec 31, 2014 | 143.17 Mn |